Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clevudine + tenofovir
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Clevudine + tenofovir is a combination of two antiviral agents used primarily in the treatment of chronic hepatitis B virus (HBV) infection. Both drugs act as inhibitors of the viral reverse transcriptase enzyme but through distinct mechanisms. Tenofovir is a nucleotide analog reverse transcriptase inhibitor (nRTI) that works by being incorporated into viral DNA and causing chain termination during replication[3][5][8]. Clevudine is a nucleoside analog that inhibits HBV DNA polymerization at the priming stage and also inhibits DNA chain elongation in a noncompetitive manner without being incorporated into the viral genome[6]. This combination may offer synergistic effects against HBV by targeting different steps in the viral replication process. Tenofovir is also widely used for HIV-1 infection as part of antiretroviral therapy regimens[2][3][4].
- Other names
- clevudinetenofovir disoproxil fumaratetenofovir DF
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on clevudine + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clevudine + tenofovir.